EMEA Recommends Orphan Drug Designation for AX200 in the Treatment of Spinal Cord Injury


<p>HEIDELBERG, Germany, Sept. 18, 2008 &ndash;SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today announced that it has received a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) for AX200 in the treatment of spinal cord injury…</p>